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A B S T R A C T
Garcinia mangostana L. (Fruit) has been commonly used as folklore drug in the treatment of
various types of diseases. The present experiment was designed to evaluate the potential
effect of α-mangostin mediated pharmacological modulation of hepatic carbohydrate me-
tabolism in streptozotocin (STZ) induced diabetic rats. Oral glucose tolerance test (OGTT)
* Corresponding author. Department of Pharmaceutical Sciences, Faculty of Health Sciences, Sam Higginbottom Institute of Agricul-
ture, Technology & Sciences, Allahabad, Uttar Pradesh, India 211007.
E-mail address: phvikas@gmail.com; vikas.kumar@shiats.edu.in (V. Kumar).
** Corresponding author. Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
E-mail address: firoz_anwar2000@yahoo.com (F. Anwar).
*** Corresponding author. Department of Pharmaceutical Sciences, Faculty of Health Sciences, Sam Higginbottom Institute of Agricul-
ture, Technology & Sciences, Allahabad, Uttar Pradesh, India 211007.
E-mail address: amitaverma.dr@gmail.com; amita.verma@shiats.edu.in (A. Verma).
1 Both authors (Vikas Kumar and Prakash Chandra Bhatt) equally contributed.
http://dx.doi.org/10.1016/j.bjbas.2016.07.001
2314-8535/© 2016 Beni-Suef University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
b en i - s u e f un i v e r s i t y j o u rna l o f b a s i c and a p p l i e d s c i e n c e s 5 ( 2 0 1 6 ) 2 5 5 – 2 7 6
Available online at www.sciencedirect.com
journal homepage: www.elsevier.com/ locate /b jbas
HOSTED BY
ScienceDirect
was performed in normoglycemic rats. Single intraperitoneal injection of STZ (60 mg/kg,
body weight) was used for induction the diabetes in Swiss albino (Wistar strain) rats. The
rats were divided into different groups. Blood glucose level, body weight, insulin, glycated
hemoglobin and hemoglobin levels were recorded at regular intervals. Biochemical param-
eters, liver enzymes, lipid profile, antioxidant parameters and inflammatory cytokine
mediators were also scrutinized. Histopathology study of kidney, pancreas and liver were
performed. The result of OGTT study depicted the better utilization of glucose in experi-
mental rats. STZ induced diabetic rats treated with α-mangostin (25, 50 and 100 mg/kg,
p.o.) and glibenclamide depicted the decline in the level of blood glucose; enhanced body
weight and showed the better utilization of glucose by different organs. STZ induced
diabetic rats treated with α-mangostin illustrated the increased level of plasma insulin,
hemoglobin, hexokinase, HDL, total protein, SOD, CAT, GSH and declined level of glycated
hemoglobin, fructose-1-6-biphosphatase, glucose-6-Phosphatase, TC, TG, LDL, VLDL, CRE,
BUN, SGOT, SGPT, ALP and LPO at effective dose dependent manners. Histological study
showed the inflamed blood vessels in diabetic kidney, which was less in α-mangostin
treated rats; diabetic pancreatic showed the complete damage of β cells, islets, aciini and
producing necrosis, but all damage was less obvious in α-mangostin treating group rats;
diabetic liver showed the damage of hepatocytes as well as central vein but was less in
treated groups. Considering the above results, α-mangostin shows potential to develop a
medicine for diabetes, hyperlipidemia, renal and hepatic protection as combinational or
mono-therapy.
© 2016 Beni-Suef University. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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1. Introduction
Over 2000 years ago, diabetes mellitus (DM) firstly appeared
in medicinal text (Orhan et al., 2012). DM is a very common
health problem, the incidence of this disease rapidly
increases day by day, worldwide (Arunachalam and
Parimelazhagan, 2013). DM is a chronic disorder of derange-
ment of carbohydrate, protein and fat metabolism distinguished
by enhanced blood glucose level and causes a defect in the
action of insulin, insulin secretions or both conditions
(Irudayaraj et al., 2012). During hyperglycemia starts the
production of non enzymatic glycation of protein and reac-
tive oxygen species (ROS), which plays an important role in
the development of DM complications (Dewanjee et al., 2009).
Oxidative stress plays an important role in the development
of diabetes pathology and an essential trigger in complex
series of events, which starts the enhancement of the occur-
rence of atherosclerosis. Antioxidants play an important role
in the tissue protection from ROS and oxidative stress.
Antioxidant also enhances the immune system and decline
the risk factor of diabetes (Deore et al., 2011). A lot of natural
sources based drug are worldwide Known as hypoglycemia
(Ahmed et al., 2014, 2015), antioxidant or both activities
(Kumar et al., 2014). A lot of synthetic drugs viz., biguanide,
sulfonylureas, α-glycosidase inhibitors, meglitinides,
thiazolidinedione, dipeptidyl peptidase-4 inhibitors and insulin
are available in market, but no one drug gives the long
duration of action to controlling the blood glucose level
without causing any adverse side effects (Lee et al., 2012;
Singh et al., 2007; Xing et al., 2009). Due to a short action of
synthetic drug along with adverse side effects, there is
growing interest in using plant based drugs, remedies, or
isolated compounds in the treatment of diabetes (Sunil et al.,
2012). Plant derived drugs and their products have attracted
not only curing the diseases and health problems, but also
take part in the development of new drugs discovery. The
plant derived drug discovery developments are still major
focusing on the development of therapeutics for various
types of diseases including diabetes. Although the availabil-
ity of known antihyperglycemicmedicine on the pharmaceutical
market, researcher still searching the new source of plant
based drug with effectual action with fewer side effects in
diabetes mellitus complications (Badole and Bodhankar, 2010).
The World Health Organization (WHO) expert committee has
recommended that more studies on plant based drugs and
their isolated compounds for the treatment of DM (World
Health Organization, 1980). According to WHO, plant based
drugs are very effective in the management of diabetes with
less or no side effects and are very low cost effective drugs.
Metformin (Galega officinalis) is an approved herb used as an
antidiabetic drug which is obtained from plant source (Marles
and Farnsworth, 1995). This viewpoint outlines the opportu-
nity that exists for these herbs in the management of diabetes
and the state of the evidence for their clinical antidiabetic
efficacy (Vuksan and Sievenpiper, 2005).
Nowadays, a lot of researchers and scientists are working
on natural plant based drugs as validation of the immense po-
tential of traditional medicinal plants in whole over world
(Gupta et al., 2010). Ethanobotanical history showed that the
more than 800 plants are used as traditional remedies in the
treatment of diabetes mellitus.
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Garcinia mangostana L. (Clusiaceae), commonly known as
mangosteen, is a slow-growing tropical evergreen tree with gla-
brous and leathery leaves. The height of plant is 6–25 m and
is commonly found in India, Myanmar, Sri Lanka, and Thai-
land. The color of fruit Garcinia mangostana L. and is red-
purple to dark purple in color. The edible aerial part of fruit
is white, juicy, spongy, and slightly acidic in taste with pleas-
ant aroma (Martin, 1980).The pericarp of mangosteen has been
used inThai indigenous medicine for the treatment of skin in-
fections, wounds, and diarrhea for many years (Gupta et al.,
2010; Martin, 1980). Recently, products manufactured from
G. mangostana have been used as a botanical dietary supple-
ment mainly in United States, due to potent antioxidant activity
(Mahabusarakam et al., 1987). The major secondary metabo-
lites of mangosteen have been found to be prenylated xanthone
derivatives (Moongkarndi et al., 2004; Nguyen et al., 2005;
Suksamrarn et al., 2002, 2003). Some members of this com-
pound class isolated from this plant possess antifungal
(Gopalakrishnan et al., 1997), antimicrobial (Suksamrarn et al.,
2002), antioxidant (Yoshikawa et al., 1994) and cytotoxic ac-
tivities (Ho et al., 2002). Antioxidants play an important role
in inhibiting and scavenging free radicals, thus providing pro-
tection against infection and degenerative diseases viz., diabetes,
cancer, virus, etc.
From this viewpoint, the present study was carried out to
evaluate the potential effect of α-mangostin mediated phar-
macological modulation of hepatic carbohydrate metabolism
in diabetic rats.
2. Material and methods
2.1. Drugs/chemicals
α-Mangostin (Fig. 1a) was a kind gift received fromAIMIL Phar-
maceuticals, New Delhi. Streptozotocin (Sigma Chemical Co.
USA), GOD/POD kit, Cholesterol kit,Triglyceride kit, (Span, India),
Glibenclamide (Ranbaxy, India), Carboxyl methyl cellulose (CMC)
(SD fine, India) were purchased from respective vendors. The
entire reagent utilized for experimental protocol was of ana-
lytical grade and used without further purification.
2.2. Molecular docking studies
The molecular docking study was carried out on 3D structure
of 11-β-hydroxysteroid dehydrogenase complex enzyme using
Maestro 9.0 program (Schrodinger Inc. USA) with 64 bits op-
erating systems underWindows 7 with an HCl computer [Intel
(R) Core (TM) i5-2400 CPU @ 3.10 GHz, 8 GB memory]. The
enzyme used in the study was taken from Protein Data Bank
(PDB ID: 2BEL) which has 96% similarity with the human cell
enzyme and all active site residues in the vicinity of cofactor
have exact counterparts and the structure was refined as
follows.The enzyme structure was checked for missing atoms,
bonds and contacts. Water molecules and all residues other
than ligand were manually deleted. The ligand molecule was
constructed using the builder molecule and were energy
a
b c
Fig. 1 – a: Structure of α-mangostin, b,c: Ligand 3D structure.
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minimized. The active site was generated using the grid box.
The lowest energy conformation was selected and subjected
to an energy minimization.
2.3. Animals
Swiss albino (Wistar strain) rats (sex, male), 175 to 200 g body
weight, were kept in individual polyethylene cages and housed
in an air conditioned room at 20 ± 2 °C; 40–60% humidity
with 12 h light and 12 h dark circle; at the animal house
facility of Siddhartha Institute of Pharmacy, Dehradun,
Uttarakhand, India, in accordance with Animal Ethical Com-
mittee of Siddhartha Institute of Pharmacy and Institutional
Animal Ethics Committee (IAEC) recognized by the Commit-
tee for the Purpose of Control and Supervision of Experiments
on Animals (CPCSEA), Government of India, for care and use
of laboratory animals.
2.4. Acute oral toxicity study
The oral study of α-mangostin was tested for short term and
acute toxicity on Wistar rats. During the acute toxicity study,
all rats were randomly divided into different groups and each
group contain 6 animals; all grouped animals received the
graded doses of α-mangostin (0.01, 0.05, 0.25, and 1.25 g kg−1)
and were observed for following parameters viz., neurologi-
cal, behavioral and autonomic changes for 48 hours (Kumar
et al., 2013a, 2013b, 2013c).
To estimate short term toxicity, rats were randomly divided
into 5 groups (6 animals; 3 male and 3 female) and each group
received the graded doses (single dose daily per oral) of
α-mangostin for 28 days. All animals were monitored for any
toxicity, clinical symptoms and adverse reactions. Body weight,
water and food consumption were monitored at regular in-
terval. Blood was collected from all animals into the heparinzed
tubes, for estimation of the hematological and biochemical
parameters.
2.5. Effect of α-mangostin on glucose-loaded model (oral
glucose tolerance test)
Oral glucose tolerance test (OGTT) test was performed on over-
night (12 h) starvingWistar rats.The rats were randomly divided
into seven groups and each group contains 6 rats (Kumar et al.,
2013a, 2013b, 2013c). Group I: rats were treated with vehicle
only, Group II: rats were treated with α-mangostin 100 mg/
kg, body weight, Group III: rats were treated with glucose 2 g/
kg, body weight, Group IV: rats were treated with α-mangostin
25 mg/kg, body weight, Group V: rats were treated with
α-mangostin 50 mg/kg, body weight, GroupVI: rats were treated
with α-mangostin 100 mg/kg, body weight, and GroupVII: rats
treated with Glibenclamide 10 mg/kg, body weight. All group
rats received the per-determined doses after receiving the 2 mg/
kg of glucose except for normal control group rats who were
treated with α-mangostin (100 mg/kg). To determine blood
glucose level, blood was collected from the tail vein at regular
intervals (0, 30, 60, 90, 120, and 150 min).The blood glucose level
of all groups rat was determined by GOD-POD kit following the
given instruction by manufacturer.
2.6. Induction of diabetes
Swiss albino (Wistar strain) rats were used for experimental
study. Before the experimentation all rats were starving over-
night (12 h). Single intraperitoneal injection of STZ
(streptozotocin) (60 mg/kg, body weight) prepared by STZ dis-
solving in 0.1 M citrate buffer (pH = 4. 5). Rats of normal control
and normal control group treated with α-mangostin (100 mg/
kg) received equal volume of vehicle. After 7 days, diabetes was
confirmed by elevating the blood glucose level and the rats
having blood glucose level more than 250 mg/dl used for study
(Ahmed et al., 2013).
2.7. Experimental study design
Diabetic rats randomly divided into following groups. Group
I: rats were treated with vehicle only; Group II: rats were treated
with α-mangostin 100 mg/kg, body weight; Group III: rats were
treated with STZ only, body weight; Group IV: rats received
STZ + α-mangostin 25 mg/kg, body weight; Group V: rats re-
ceived STZ + α-mangostin 50 mg/kg, body weight; GroupVI: rats
received STZ + α-mangostin 100 mg/kg, body weight; GroupVII:
rats received STZ + Glibenclamide 10 mg/kg, body weight. All
group rats received the oral administration of different doses
of α-mangostin and glibenclamide through the intragastric tube
for 56 days.
2.7.1. Biochemical estimation
All group rats were starved overnight and blood sample was
withdrawn from tail vein. The blood was withdrawn from the
all groups of rats at regular time intervals (1st 28th and 56th
day). Plasma insulin level and blood glucose level were deter-
mined by using the reported method of Zheng et al., 2012 with
minor modification (Zheng et al., 2012). The body weight of all
group rats was estimated at regular intervals. End of experi-
mental study (56th day), all group animals were fasted overnight
and blood samples were collected from tail vein for the esti-
mation of biological parameters viz., hexokinase, glucose-6-
phosphatase, fructose-16-bisphosphatase; lipid parameters viz.,
total cholesterol (TC), total triglyceride (TG), low density lipo-
protein cholesterol (LDL), high density lipoprotein cholesterol
(HDL) and very low density lipoprotein (VLDL) (Kumar et al.,
2013a, 2013b, 2013c). The coronary risk index and athero-
genic index were calculated using the described formula
Atherogenic Index
Low density lipoprotein cholesteol LDL
High d
=
( )
ensity lipoprotein cholesterol HDL( )
Coronary Risk Index
Total Cholesterol TC
High density lipoprote
=
( )
in cholesterol HDL( ) .
The ponderal homogeneity index (iPH) and ponderal grain
(PG) were calculated by using the following formula.
iPH Wi
Wi
Wi Wh
=
+( )2
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PG
Wf Wi
Wf
=
−
×
( )
100
WhereWi = initial body weight; Wh = highest body weight;
Wf = final body weight.
2.7.2. Estimation of antioxidant markers
The antioxidant marker parameters including lipid peroxidation
(LPO) in tissue was evaluated by using the reported method
of Ohkawa et al., 1979 with minor modification (Ohkawa et al.,
1979), superoxide dismutase (SOD) and catalase (CAT), reduced
glutathione (GSH) were estimated by reported method
EI-Beshbishy (2005; Anwar et al., 2015; Kumar et al., 2015a, 2015b;
Verma et al., 2016).
2.7.3. Estimation of renal parameters
Renal parameters such as creatinine (CRE), total blood urea ni-
trogen (BUN) and glycated serum protein (GSP) were evaluated
by using the diagnostic kit according to manufacturer’s
instruction.
2.7.4. Estimation of serum CRP, TNF-α and IL-6
The level of CRP, TNF-α and IL-6 were estimated by according
to the manufacture’s instruction using the ELISA method.
2.8. Data analyses
Statistical analyses were executed by Graphpad prism soft-
ware. Results were presented as mean value ± standard
deviation. The Dunnett’s test was performed for analysis the
data, respectively.
3. Result
3.1. Molecular docking study
Docking of α-mangostin with 11-hydroxysteroid dehydroge-
nase (PDB ID: 2BEL) active site revealed several molecular
interactions (hydrogen bond and hydrophobic interactions)
were considered to be responsible for the observed affinity of
compound. In contrast, α-mangostin lacks of Zwitter ion but
its form hydrogen bonds to enzyme through its amino and
carbonyl group with SER169 residue, that is at the same
residue where the natural inhibitors bind. Hydrogen bond
interaction between active hydrogen (—H—O—) of α-mangostin,
as it acts as a hydrogen bond donor with the carboxyl group
(C=O) of side chain residue of SER169 (1.90 Å) as it act as
hydrogen bond acceptor. Further, second Hydrogen bond
interaction with ring oxygen g (—O—) of compound as it acts
as the hydrogen bond acceptor and an amino group (N—H)
of side chain residue of SER170 (2.10 Å) as it acts as hydrogen
bond donor (Figs. 2 and 3). The hydroxyl compound group
seems to have an important role in strong hydrogen bonding
because the lone pair of electrons of nitrogen atoms of
amide delocalized into carbonyl group of compounds. In
addition to many hydrophobic interactions between phenyl
ring and a side group with rest amino acid residues were
shown in Lig plot (Fig. 3). The glide score value of the
compound was found to be −7.94 as it indicated that the
molecule interacts better with the enzyme.
Docking of compound into the enzyme Fructose-1,
6-bisphosphatase 1 (PDB ID: 2JJK) active site revealed that several
molecular interactions (hydrogen bond and hydrophobic
Fig. 2 – Binding patterns of compound α-mangostin into the binding sites of 11-β-hydroxysteroid dehydrogenase (PDB ID:
2BEL) showing hydrogen bond (yellow dotted lines) with SER169 (1.90 Å) and with SER170 (2.10 Å).
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interactions) were considered to be responsible for observed
affinity of compound. In contrast, compound lacks Zwitter ion
but its form hydrogen bonds to the enzyme through its amino
and carbonyl group with SER169 residue that is at the same
residue where the natural inhibitors bind. Hydrogen bond in-
teraction between the active hydrogen (—H—O—) of compound
as it acts as a hydrogen bond donor with the carboxyl group
(C=O) of side chain residue of ARG C:22 (2.4938 Å) as it act as
hydrogen bond acceptor. Further second Hydrogen bond in-
teraction with ring oxygen g (—O—) of the compound as it acts
as the hydrogen bond acceptor and an amino group (N—H) of
the side chain residue of GLY A:26 (2.002 Å) as it acts as hy-
drogen bond donor (Figs. 4 and 5). The hydroxyl group of the
compound seems to have an important role in strong hydro-
gen bonding because the lone pair electrons of nitrogen atom
of the amide delocalized into the carbonyl group of com-
pounds. In addition to many hydrophobic interactions between
the phenyl ring and a side group with the rest amino acid resi-
dues were shown in Lig plot (Fig. 5). The glide score value of
the compound was found to be −6.449 as it indicated that the
molecule interacts better with the enzyme.
Docking study of the glibenclamide (Fig. 6) into the enzyme
11-hydroxysteroid dehydrogenase (PDB ID: 2BEL) active site
showed the several molecular interactions (hydrogen bond and
hydrophobic interactions) were considered to be responsible
for the observed affinity of the glibenclamide. In contrast,
glibenclamide lacks Zwitter ion but it forms hydrogen bonds
with the enzyme through its amino and carbonyl groups with
the LEU 215 residue that is at the same residue where the
natural inhibitors bind. Hydrogen bond interaction between the
active hydrogen (—H—O—) of the compound as it acts as a hy-
drogen bond donor with the carboxyl group (C=O) of the side
chain residue of LEU 215 (1.71 Å) as it acts as hydrogen bond
acceptor. Further second Hydrogen bond interaction with ring
oxygen g (—O—) of the compound as it acts as the hydrogen
bond acceptor and an amino group (N—H) of the side chain
residue of SER170 (2.15 Å) as it acts as hydrogen bond donor
(Figs. 7 and 8). The hydroxyl group of the compound seems to
have an important role in strong hydrogen bonding because
the lone pair of electrons of nitrogen atoms of the amide de-
localized into the carbonyl group of compounds. In addition
to many hydrophobic interactions between the phenyl ring and
a side group with the rest of the amino acid residues were
shown in Lig plot (Fig. 8). The glide score value of the com-
pound was found to be −7.33 as it indicated that the molecule
interacts better with the enzyme.
Docking study of the glibenclamide into the enzyme
Fructose-1, 6-bisphosphatase 1 (PDB ID: 2JJK) active site showed
that several molecular interactions (hydrogen bond and hy-
drophobic interactions) were considered to be responsible
for the observed affinity of the glibenclamide. (——) — Further,
second Hydrogen bond interaction with ring oxygen g (-O-)
of the compound acts as the hydrogen bond acceptor and an
amino group (N-H) of the side chain residue of THR A: 31
(2.39 Å) act as hydrogen bond donor (Figs. 9 and 10). The
hydroxyl group of the compound seems to have an impor-
tant role in strong hydrogen bonding because the lone pair
of electrons of nitrogen atoms of the amide delocalized into
Fig. 3 – Lig plot of compound α-mongestin displays interaction with the binding sites of 11-β-hydroxysteroid
dehydrogenase enzyme (PDB ID: 2BEL) showing hydrogen bond (pink dotted lines) with SER169 (1.90 Å) and with SER170
(2.10 Å).
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the carbonyl group of compounds. In addition to many
hydrophobic interactions between the phenyl ring and a side
group with the rest of the amino acid residues were shown
in Lig plot (Fig. 10). The glide score value of the compound
was found to be −7.36 as it indicated that the molecule
interacts better with the enzyme.
3.2. Acute oral toxicity
Oral administration of α-mangostin did not show any sign and
symptoms of toxicity, mortality, behavioral changes and none
of any other types of adverse reaction during the study period.
During the specified study period, no difference was
Fig. 4 – Binding patterns of compound α-mongestin into the binding sites of fructose-1, 6-bisphosphatase 1 (PDB ID: 2JJK)
showing hydrogen bond (yellow dotted lines) with ARG 22 (2.49 Å) and with GLY 26 (2.00 Å).
Fig. 5 – Lig plot of compound α-mongestin display interaction into the binding sites of fructose-1,6-bisphosphatase 1 (PDB
ID: 2JJK) showing hydrogen bond (pink dotted lines) with ARG 22 (2.49 Å) and with GLY 26 (2.00 Å).
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observed in body weight and food consumption when com-
pared to normal control group rats. Other parameters viz.,
hepatic, renal and hematological profile remained unchanged
after 28 days of utilization (Table 1). Oral administration of
α-mangostin did not produce any toxic effect in rats till the
dose 1250 mg/kg body weight therefore, further experimenta-
tion of antidiabetic activity of α-mangostin was carried out using
25, 50 and 100 mg/kg dose levels.
3.3. Effect of α-mangostin on blood glucose tolerance test
The acute effect of α-mangostin on blood glucose level was
evaluated using an oral glucose tolerance test on overnight
fasted rats. After receiving glucose; glucose control group rats
showed the increased area under control (AUC) of blood glucose
(Table 2). While α-mangostin received rats showed the de-
clined level of blood glucose AUC at dose dependent manner
(Fig. 3). Oral administration of α-mangostin significantly
(P < 0.001) reduced the blood glucose level by 13.58%, 24.07%
and 37.45% at the tested doses of 25 mg/kg, 50 mg/kg and
100 mg/kg respectively, after glucose administration in rats.
3.4. Effect of α-mangostin on blood glucose
The blood glucose level of normal control and experimental
rats was estimated at regular intervals. Normal control and
normal control group rats treated with α-mangostin (100 mg/
kg) did not show any change in blood glucose level till end of
experimental periods. STZ induced diabetic rats showed the
enhanced blood glucose level at end of the study. STZ induced
diabetic rats treated with α-mangostin (25, 50 and 100 mg/kg)
had significantly (P < 0.001) declined blood glucose level at ef-
fective dependent manner. α-Mangostin dose of 100 mg/kg, b.w.
showed the maximum declined blood glucose at end of the
study. STZ induced diabetic rats treated with glibenclamide
(standard drug) showed the declined level of blood glucose
(Table 3).
Fig. 6 – Structure of Glibenclamide.
Fig. 7 – Binding patterns of Glibenclamide into the binding sites of 11-β-hydroxysteroid dehydrogenase (PDB ID: 2BEL)
showing hydrogen bond (yellow dotted lines) with LEU 215 (1.71 Å), SER170 (2.15 Å) and with TYR 183 (2.43 Å).
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3.5. Effect of α-mangostin on weight variation
The PG and iPH for normal control and experimental diabetic
ratswere calculated and summarized inTable 4.Endof the study,
STZ induceddiabetic rats demonstrated thedeclinedbodyweight
as compared to normal control group rats. STZ induced dia-
betic rats treated with α-mangostin (25, 50 and 100 mg/kg) and
glibenclamide significantly (P < 0.001) enhanced the bodyweight
atdosedependentmanner.α-Mangostin25mg/kgproduced196 g
(3.78%), 50 mg/kg 206.8 g (6.74%) and 100 mg/kg 209 g (11.49%)
Fig. 8 – Lig plot of Glibenclamide display interaction into the binding sites of 11-β-hydroxysteroid dehydrogenase enzyme
(PDB ID: 2BEL) showing hydrogen bond (pink dotted lines) with LEU 215 (1.71 Å), SER170 (2.15 Å) and with TYR 183 (2.43 Å)
and, Pi–Pi interaction with TYR 183 (4.59 Å).
Fig. 9 – Binding patterns of Glibenclamide into the binding sites of fructose-1, 6-bisphosphatase 1 (PDB ID: 2JJK) showing
hydrogen bond (yellow dotted lines) with THR A: 31 (2.39 Å) and with GLY C: 28 (1.98 Å).
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Fig. 10 – Lig plot of Glibenclamide display interaction into the binding sites of fructose-1,6-bisphosphatase 1 (PDB ID: 2JJK)
showing hydrogen bond (pink dotted lines) with THR A: 31 (2.39 Å) and with GLY C: 28 (1.98 Å).
Table 1 – Effect of 28 day repeated oral administration of α-mangostin on biochemical and hematological parameters of
rats.
S. No Sex Parameter Toxicity study
Normal
control
α-Mangostin
(10 mg /kg)
α-Mangostin
(50 mg/kg)
α-Nangostin
(250 mg/kg)
α-Mangostin
(1250 mg/kg)
General effect
1 Male Body weight (g) 172 ± 4.34 168.4 ± 2.21 176 ± 4.32 181.43 ± 3.84 192 ± 3.54
2 Male Water intake (mL) 108 102 105 110 115
3 Male Food intake (gm) 65 64 68 71 74
1 Female Body weight (gm) 123 ± 2.84 118 ± 1.82 122 ± 2.54 129 ± 3.84 131 ± 1.32
2 Female Water intake (mL) 78 70 76 80 84
3 Female Food intake (gm) 40 38 41 42 41
Hematological parameters
1 Male RBC (106/cu mm) 6.46 ± 0.98 7.21 ± 1.07 6.65 ± 1.45 8.41 ± 1.94 8.32 ± 1.63
2 Male WBC (103/cu mm3) 9.87 ± 1.11 10.73 ± 1.84 11.21. ± 1.82 9.92 ± 1.21 9.96 ± 1.93
3 Male Hb (g dL−1) 14.21 ± 1.92 13.41 ± .98 13.98 ± 1.09 14.31 ± 1.92 14.11 ± 0.92
4 Male Platelet (105/cu mm) 4.32 ± 0.42 5.8 ± 0.93 6.7 ± 1.03 4.78 ± 0.93 4.57 ± 0.73
1 Female RBC (106/cu mm) 5.94 ± 0.87 5.64 ± 1.21 5.87 ± 1.92 6.11 ± 0.93 6.16 ± 0.98
2 Female WBC (103/cu mm3) 8.65 ± 1.09 9.92 ± 1.14 10.8 ± 1.08 9.01 ± 1.22 8.87 ± 1.74
3 Female Hb (g dL−1) 15.32 ± 1.93 16.67 ± 1.83 16.21 ± 2.93 15.94 ± 1.98 15.45 ± 1.73
4 Female Platelet (105/cu mm) 4.01 ± 0.31 3.98 ± 1.83 4.2 ± 0.97 4.6 ± 1.04 5.04 ± 0.82
Biochemical parameters
1 Male Bilirubin (mg dL−1) 0.48 ± 0.07 0.51 ± 0.04 0.54 ± 0.09 0.52 ± 0.07 0.50 ± 0.06
2 Male Creatinine (mg dL−1) 0.76 ± 0.21 0.86 ± 0.63 0.91 ± 0.84 0.88 ± 0.92 0.79 ± 1.01
3 Male Urea (mg dL−1) 41 ± 3.43 36.2 ± 2.34 40.83 ± 2.91 43.8 ± 4.53 42.6 ± 2.32
4 Male ALP (UL−1) 288.2 ± 31.5 301 ± 40.3 321.6 ± 32.5 358 ± 39.8 313.5 ± 29.4
5 Male ALT (UL−1) 75.9 ± 4.32 61.5 ± 5.31 66.9 ± 3.41 70.42 ± 4.52 72.4 ± 2.76
6 Male AST (UL−1) 121.4 ± 10.4 124.6 ± 10.8 132 ± 9.82 124 ± 12.43 113 ± 8.92
1 Female Bilirubin (mg dL−1) 0.43 ± 0.04 0.41 ± 0.08 0.39 ± 0.06 0.44 ± 0.03 0.45 ± 0.08
2 Female Creatinine (mg dL−1) 0.65 ± 0.98 0.61 ± 1.24 0.64 ± 1.73 0.69 ± 1.92 0.72 ± 1.62
3 Female Urea (mg dL−1) 35 ± 2.23 35.1 ± 4.32 33 ± 3.94 36.4 ± 1.94 38.8 ± 2.08
4 Female ALP (UL−1) 250.2 ± 22.9 275.9 ± 32.8 279 ± 26.98 301.92 ± 30.21 312 ± 28.72
5 Female ALT (UL−1) 65.55 ± 2.32 64.53 ± 3.44 60.3 ± 2.83 62.93 ± 4.93 59.3 ± 2.93
6 Female AST (UL−1) 99.8 ± 11.22 111.2 ± 14.32 118 ± 10.92 107.2 ± 9.02 98.4 ± 10.23
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confirm the increased body weight respectively, when com-
pared to STZ induced diabetic control group rats 175 g (−2.85%).
3.6. Effect of α-mangostin on insulin, HOMA-IR,
HOMA-β hemoglobin and glycated hemoglobin
Table 5 clearly depicted the effect of α-mangostin on insulin,
hemoglobin and glycated hemoglobin in normal control and
experimental animals. STZ induced diabetic rats showed the
increased level of glycated hemoglobin and decreased plasma
insulin and hemoglobin levels. Oral administration of
α-mangostin significantly (P < 0.001) enhanced the level of
insulin, hemoglobin and declined the level of glycated hemo-
globin. STZ induced diabetic rats treated with α-mangostin
showed the protective effect against insulin resistance at
effective dose dependent manner.
Table 2 – Pharmacokinetic parameters effect of α-mangostin on blood glucose levels in oral glucose tolerance test in
normoglycemic rats.
S. No Groups Pharmacokinetic parameters
Cmax
(mg/dl)
tmax
(min)
AUC
(mg.min/dl)
1 Glucose control 144.8 ± 2.341 30 17794.5
2 α-Mangostin (25 mg/kg) 139.2 ± 1.497 30 16779
3 α-Mangostin (50 mg/kg) 135.8 ± 2.321 30 15937.5
4 α-Mangostin (100 mg/kg) 125.3 ± 1.356 30 13878
5 Glibenclamide (10 mg/kg) 128.3 ± 1.548 30 14496
Each parameter represents the mean of Six animals. Area under curve (AUC) values. tmax, time at maximum observed concentration; Cmax,
maximum concentration.
Table 3 – Effect of α-mangostin on blood glucose level in normal & STZ induced diabetic treated rats.
S. No Groups Blood glucose level in mg/dL at different
time interval of experimentation
On 1st day On 28th day On 56th day
1 Normal control 79.8 ± 1.023 83.5 ± 0.934 84.1 ± 1.254
2 Normal control + α-mangostin (100 mg/kg) 80.6 ± 1.208 81.2 ± 1.034 83.5 ± 1.039
3 Diabetic control 322.4 ± 2.768 403.3 ± 2.039 481.6 ± 2.383
4 α-Mangostin (25 mg/kg) 320.6 ± 1.923ns 225.2 ± 1.093*** 190.4 ± 1.839***
5 α-Mangostin (50 mg/kg) 320 ± 1.871ns 202.5 ± 1.536*** 134.2 ± 1.092***
6 α-Mangostin (100 mg/kg) 324.2 ± 1.563ns 183.4 ± 1.021*** 96.8 ± 1.732***
7 Glibenclamide (10 mg/kg) 327.5 ± 2.514ns 188.3 ± 1.032*** 101.6 ± 0.928***
The data are expressed as mean ± SEM. (n = number of animals in each group = 6). The comparisons were made by one way ANOVA followed
by Dunnett’s test. ns = non-significant, STZ = Streptozotocin.
*p < 0.05 is considered as very significant when compared to the control group.
**p < 0.01 is considered as very significant when compared to the control group.
*** p < 0.001 is considered as extremely significant when compared to the control group.
Table 4 – Effect of α-mangostin on body weight and ponderal homogeneity index (iPH) and ponderal gain (PG) of STZ
induced diabetic and normal control rats.
S. No Groups Initial weight (g) Final weight (g) iPH PG
1 Normal control 178.8 ± 1.462 198.4 ± 1.544 0.948 9.879
2 Normal control + α-mangostin (100 mg/kg) 185.2 ± 1.885 205.8 ± 1.748 0.947 10.001
3 Diabetic control 180 ± 1.951 180.2 ± 2.286 1.014 0.111
4 α-Mangostin (25 mg/kg) 188.6 ± 1.784 196 ± 1.249** 0.981 3.775
5 α-Mangostin (50 mg/kg) 193 ± 3.036 206.8 ± 3.467*** 0.965 6.673
6 α-Mangostin (100 mg/kg) 185 ± 1.428 209 ± 1.108*** 0.939 11.483
7 Glibenclamide (10 mg/kg) 198.4 ± 1.841 220 ± 1.239*** 0.948 9.818
The data are expressed as mean ± SEM. (n = number of animals in each group = 6). The comparisons were made by one way ANOVA followed
by Dunnett’s test. ns = non-significant, STZ = Streptozotocin.
*p < 0.05 is considered as very significant when compared to the control group.
** p < 0.01 is considered as very significant when compared to the control group.
*** p < 0.001 is considered as extremely significant when compared to the control group.
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3.7. Effect of α-mangostin on hepatic enzymes
Table 6 represented the efficacy of α-mangostin on hepatic
enzymes viz., hexokinase, glucose-6-phosphatase and fruc-
tose 1–6 biphosphate in STZ induced diabetic rats. Increased
levels of glucose-6-phosphatase, fructose 1–6 phosphatase and
decreased level of hexokinase, glucose-6-phosphate
dehydrogensae was observed in STZ induced diabetic rats. STZ
induced diabetic rats treated with α-mangostin (25, 50 and
100 mg/kg) and glibenclamide significantly (P < 0.001) de-
clined the level of glucose-6-phosphatase, fructose-6-
phosphatase and increased level of hexokinase at effective dose
dependent manner.
3.8. Effect of α-mangostin on lipid profile
Table 7 clearly illustrated the effect of α-mangosteen on lipid
profile of STZ induced diabetic rats. Table 7 showed the in-
creased level of total cholesterol, LDL cholesterol, VLDL
cholesterol, triglyceride and declined level of HDL cholesterol
in STZ induced diabetic rats. STZ induced diabetic rats treated
with different doses of α-mangostin significantly (P < 0.001)
altered the lipid profile as compared to STZ induced diabetic
rats.
3.9. Effect of α-mangostin on atherogenic index and
coronary risk index
STZ induced diabetic control group rats showed the en-
hanced level of atherogenic index and coronary risk factor as
compared to normal control and normal control group rats
treated with α-mangostin 100 mg/kg (Table 8). STZ induced dia-
betic rats treated with α-mangostin showed the inhibition of
atherogenic index and coronary risk factor at effective dose
dependent manner.
3.10. Effect of α-mangostin on renal function parameters
As the evidence from Table 9 that untreated diabetic rats
showed the increased level of BUN, serum creatinine and de-
creased level of total protein. STZ induced diabetic rats, orally
treated with α-mangostin decreased the level of BUN, serum
Table 5 – Effect of α-mangostin on biochemical parameters in STZ-induced diabetic rats.
S. No Groups Biochemical parameters
Plasma
insulin
(µU/mL)
Glycated
hemoglobin
(A1c) (%)
Hemoglobin
(cells/cu.mm)
HOMA-IR HOMA-β
1 Normal control 12.8 ± 0.378 5.4 ± 0.493 13.2 ± 0.374 2.80 218.38
2 Normal control + α-mangostin (100 mg/kg) 12.6 ± 0.245 5.2 ± 0.379 13.6 ± 0.245 2.59 221.26
3 Diabetic control 3.2 ± 0.393 9 ± 0.705 6.8 ± 0.374 3.81 2.75
4 α-Mangostin (25 mg/kg) 4.8 ± 0.254* 8.2 ± 0.374ns 8 ± 0.832** 2.25 ns 13.56*
5 α-Mangostin (50 mg/kg) 7.2 ± 0.832** 6.8 ± 0.272* 10 ± 0.793*** 2.38* 36.40**
6 α-Mangostin (100 mg/kg) 12 ± 0.634*** 5.2 ± 0.194*** 12.8 ± 0.375*** 2.86** 127.81***
7 Glibenclamide (10 mg/kg) 11.6 ± 0.509*** 5.8 ± 0.394*** 12.4 ± 0.593*** 2.91** 108.18***
The data are expressed as mean ± SEM. (n = number of animals in each group = 6). The comparisons were made by one way ANOVA followed
by Dunnett’s test. ns = non-significant, STZ = Streptozotocin.
* p < 0.05 is considered as very significant when compared to the control group.
** p < 0.01 is considered as very significant when compared to the control group.
*** p < 0.001 is considered as extremely significant when compared to the control group.
Table 6 – Effect of α-mangostin on hepatic enzymes in normal & STZ induced diabetic treated rats.
S. No Groups Hepatic enzyme level
Hexokinase
(µg/mg of
tissue)
Glucose-6-
phosphatase
(unit/mg of tissue)
Fructose-1-6-
biphosphatase
(unit/mg of tissue)
1 Normal control 145.2 ± 1.934 8.8 ± 0.372 28.2 ± 0.882
2 Normal control + α-mangostin (100 mg/kg) 144.2 ± 1.319 9 ± 0.316 28.8 ± 0.281
3 Diabetic control 94.6 ± 1.327 13.6 ± 0.509 60.6 ± 0.748
4 α-Mangostin (25 mg/kg) 108.2 ± 1.855* 13 ± 0.261ns 52 ± 1.923*
5 α-Mangostin (50 mg/kg) 122 ± 0.948*** 11.8 ± 0.272** 40.4 ± 1.077**
6 α-Mangostin (100 mg/kg) 138.8 ± 1.497*** 9.4 ± 1.021*** 32.8 ± 0.862***
7 Glibenclamide (10 mg/kg) 135.4 ± 1.621*** 9.8 ± 0.821*** 36.2 ± 1.821***
The data are expressed as mean ± SEM. (n = number of animals in each group = 6). The comparisons were made by one way ANOVA followed
by Dunnett’s test. ns = non-significant, STZ = Streptozotocin.
* p < 0.05 is considered as very significant when compared to the control group.
** p < 0.01 is considered as very significant when compared to the control group.
*** p < 0.001 is considered as extremely significant when compared to the control group.
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creatinine and increased the level of total protein to a mo-
mentous level in STZ induced diabetic rats. The maximum
improvement of renal parameters was observed in α-mangostin
(100 mg/kg, body weight) treated group rats as compared to un-
treated diabetic rats and other doses received rats (Table 9).
3.11. Effect of α-mangostin on hepatic function
parameters
SGOT, SGPT and ALP tests, measurement of hepatic function
tests were performed during the experimentation. STZ induced
Table 7 – Effect of α-mangostin on lipid profile in normal & STZ induced diabetic treated rats.
S. No Groups Serum lipid profile
TC
(mg/dL)
HDL
(mg/dL)
TG
(mg/dL)
LDL
(mg/dL)
VLDL
(mg/dL)
1 Normal control 78.8 ± 0.489 57.6 ± 0.812 82 ± 0.707 4.8 ± 0.839 16.4 ± 0.932
2 Normal control + α-mangostin (100 mg/kg) 78.8 ± 0.489 57.8 ± 1.068 82.2 ± 0.489 4.6 ± 0.932 16.4 ± 0.839
3 Diabetic control 129.4 ± 1.536 23 ± 0.707 138.2 ± 1.562 78.7 ± 1.292 27.64 ± 1.039
4 α-Mangostin (25 mg/kg) 107 ± 1.924* 30.2 ± 0.663** 128.2 ± 1.463* 51.1 ± 1.932** 25.64 ± 1.212ns
5 α-Mangostin (50 mg/kg) 95.2 ± 1.393** 38.8 ± 0.862*** 110.2 ± 1.068** 34.36 ± 0.932*** 22.08 ± 1.123**
6 α-Mangostin (100 mg/kg) 84.6 ± 0.927*** 50.8 ± 1.165*** 90.4 ± 1.721*** 15.72 ± 0.728*** 18.08 ± 0923***
7 Glibenclamide (10 mg/kg) 89.8 ± 0.663*** 48 ± 1.517*** 97 ± 1.143*** 22.4 ± 0.128*** 19.4 ± 1.029***
The data are expressed as mean ± SEM. (n = number of animals in each group = 6). The comparisons were made by one way ANOVA followed
by Dunnett’s test. ns = non-significant, STZ = Streptozotocin,TC = Total Cholesterol, HDL = High density lipoprotein,TG = Triglyceride, LDL = Low
density lipoprotein, VLDL = Very low density lipoprotein.
* p < 0.05 is considered as very significant when compared to the control group (0 h).
** p < 0.01 is considered as very significant when compared to the control group (0 h).
*** p < 0.001 is considered as extremely significant when compared to the control group (0 h).
Table 8 – Effect of α-mangostin on artherogenic index and coronary risk index.
S. No Groups Artherogenic index Coronary risk index
1 Normal control 0.08 ± 0.008 1.42 ± 0.083
2 Normal control + α-mangostin (100 mg/kg) 0.07 ± 0.006 1.41 ± 0.074
3 Diabetic control 3.42 ± 0.984 6.01 ± 1.252
4 α-Mangostin (25 mg/kg) 1.69 ± 0.221* 4.24 ± 0.938*
5 α-Mangostin (50 mg/kg) 0.88 ± 0.054** 2.84 ± .0738**
6 α-Mangostin (100 mg/kg) 0.31 ± 0.012*** 1.78 ± 0.225***
7 Glibenclamide (10 mg/kg) 0.46 ± 0.029*** 2.02 ± 0.431***
The data are expressed as mean ± SEM. (n = number of animals in each group = 6). The comparisons were made by one way ANOVA followed
by Dunnett’s test. ns = non-significant.
* p < 0.05 is considered as very significant when compared to the control group.
** p < 0.01 is considered as very significant when compared to the control group.
*** p < 0.001 is considered as extremely significant when compared to the control group.
Table 9 – Effect of α-mangostin on renal function parameters in normal & STZ induced diabetic treated rats.
S. No Groups Renal function parameters
Serum creatinine
(mg/dl)
Total protein
(g/dl)
BUN
(mg/dl)
1 Normal control 0.84 ± 0.261 7.2 ± 0.374 31.6 ± 1.077
2 Normal control + α-mangostin (100 mg/kg) 0.86 ± 0.0254 7.2 ± 0.283 32.6 ± 0.927
3 Diabetic control 2.02 ± 0.932 3.6 ± 0.509 90.8 ± 2.059
4 α-Mangostin (25 mg/kg) 1.45 ± 0.283* 4.6 ± 0.593* 72.8 ± 1.356*
5 α-Mangostin (50 mg/kg) 1.21 ± 0.029** 5.8 ± 0.374** 54.4 ± 1.601**
6 α-Mangostin (100 mg/kg) 0.98 ± 0.0149*** 7 ± 0.316*** 36.4 ± 1.364***
7 Glibenclamide (10 mg/kg) 1.02 ± 0.0154*** 6.7 ± 0.245*** 38.2 ± 1.281***
The data are expressed as mean ± SEM. (n = number of animals in each group = 6). The comparisons were made by one way ANOVA followed
by Dunnett’s test. ns = non-significant, STZ = Streptozotocin, BUN = Blood urea nitrogen.
* p < 0.05 is considered as very significant when compared to the control group.
** p < 0.01 is considered as very significant when compared to the control group.
*** p < 0.001 is considered as extremely significant when compared to the control group.
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diabetic rats showed the increased activities of SGOT, SGPT and
ALP. STZ induced diabetic rats treated with different doses of
α-mangostin showed declined levels of SGOT, SGPT and ALP
as compared to STZ induced untreated diabetic rats (Table 10).
Oral administration of α-mangostin (25 mg/kg, 50 mg/kg and
100 mg/kg, body weight) brought the level of SGOT, SGPT and
ALP near to normal control, similar to standard drug
(glibenclamide).
3.12. Effect of α-mangostin on antioxidant enzymes
Table 11 showed the activities of endogenous antioxidant
enzymes viz., SOD, CAT, LPO and GSH in the normal and STZ
induced diabetic rats. There was significant (P < 0.001) en-
hancement in the level of LPO and reduction in the level of
CAT, SOD, GSH was observed in STZ induced diabetic rats. STZ
induced diabetic rats treated with α-mangostin (25, 50 and
100 mg/kg, p.o.) significantly (P < 0.001) restored the endog-
enous antioxidant enzymes value near the normal level.
3.13. Effect of α-mangostin on CRP, TNF-α and IL-6
Table 12 showed the effect of α-mangostin on CRP,
TNF-α and IL-6. STZ induced diabetic control group rats
showed the enhanced level of inflammatory cytokines
viz., CRP, TNF-α and IL-6. Oral administration of α-mangostin
significantly (P < 0.001) brought back the inflammatory
level near to normal control level at dose dependent
manner.
3.14. Effect of α-mangostin on histopathology
3.14.1. Pancreas
The normal control group rat histopathology demonstrated the
normal architecture viz., average sized of islet of Langerhans
were covered the pancreatic acini as well as prominent nuclei
with arranged lobules covered by islet of Langerhans cells. STZ
induced diabetic rats showed the completely damaged β cells,
islets, acini, degeneration with asymmetrical vacuoles and ne-
Table 10 – Effect of α-mangostin on renal enzymes parameters in normal & STZ induced diabetic treated rats.
S. No Groups Liver enzymes parameters
SGOT
(U/l)
SGPT
(U/l)
ALP
(IU/dl)
1 Normal control 123 ± 1.789 89.4 ± 1.077 128.6 ± 1.364
2 Normal control + α-mangostin (100 mg/kg) 123.4 ± 2.015 88.6 ± 1.043 126.4 ± 1.503
3 Diabetic control 212.4 ± 1.288 169.4 ± 2.043 282.9 ± 2.768
4 α-Mangostin (25 mg/kg) 193 ± 1.897* 142.8 ± 1.881* 210.1 ± 1.503*
5 α-Mangostin (50 mg/kg) 164.8 ± 2.131** 125 ± 1.643** 165.3 ± 2.956**
6 α-Mangostin (100 mg/kg) 141.4 ± 1.503*** 95.2 ± 1.985*** 138.2 ± 1.691***
7 Glibenclamide (10 mg/kg) 145.6 ± 1.887*** 101.4 ± 1.536*** 146.5 ± 1.158***
The data are expressed as mean ± SEM. (n = number of animals in each group = 6). The comparisons were made by one way ANOVA followed
by Dunnett’s test. ns = non-significant, STZ = Streptozotocin, SGOT = Serum glutamic oxaloacetic transaminase, SGPT = Serum glutamic pyruvic
transaminase, ALP = Alkaline phosphate.
* p < 0.05 is considered as very significant when compared to the control group.
** p < 0.01 is considered as very significant when compared to the control group.
*** p < 0.001 is considered as extremely significant when compared to the control group.
Table 11 – Effect of α-mangostin on antioxidant enzymes in normal & STZ induced diabetic treated rats.
S. No Groups Antioxidant parameters
LPO
(µmole of
MDA/mg protein)
SOD
(units/mg
protein)
CAT
(µmole of H2O2
consumed/min/mg
of protein)
GSH
(µmole of
GSH/mg protein)
1 Normal control 7.6 ± 0.509 50.8 ± 1.881 74.4 ± 1.503 40.6 ± 1.208
2 Normal control + α-mangostin (100 mg/kg) 7.8 ± 0.372 50.6 ± 2.379 73 ± 1.225 39.6 ± 0.748
3 Diabetic control 17 ± 0.846 12.6 ± 0.927 48.4 ± 1.435 18.2 ± 1.145
4 α-Mangostin (25 mg/kg) 14 ± 0.316* 17 ± 1.581* 56.6 ± 1.288ns 24.8 ± 0.583*
5 α-Mangostin (50 mg/kg) 12.2 ± 0.374** 31 ± 1.225** 64.4 ± 1.568** 30.2 ± 0.707***
6 α-Mangostin (100 mg/kg) 8.8 ± 0.372*** 45.6 ± 1.691*** 70.2 ± 0.861*** 37.4 ± 1.327***
7 Glibenclamide (10 mg/kg) 9.4 ± 0.483*** 43.2 ± 1.241*** 68 ± 1.14*** 36.8 ± 1.158***
The data are expressed as mean ± SEM. (n = number of animals in each group = 6). The comparisons were made by one way ANOVA followed
by Dunnett’s test. ns = non-significant, STZ = Streptozotocin, LPO = Lipid peroxidation, SOD = Superoxide dismutase, CAT = Catalase, GSH = Reduced
glutathione;.
* p < 0.05 is considered as very significant when compared to the control group.
** p < 0.01 is considered as very significant when compared to the control group.
*** p < 0.001 is considered as extremely significant when compared to the control group.
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crosis changes which was followed by atrophy and fibrosis. STZ
induced diabetic rats treated with α-mangostin showed the im-
provement of marked cellular injury as well as enhanced
restoration of islet cells, producing the protective effect for β
cells and more asymmetrical vacuoles (Fig. 11).
3.14.2. Liver
Histopathology study of normal control group rats showed
the average sized hepatocytes with central vein along with
threshold triad. STZ induced diabetic rats liver histopathol-
ogy showed the damage of hepatocytes taken over macro
Table 12 – Effect of α-mangostin on serum TNF-a, IL-6 and CRP of normal & STZ induced diabetic treated rats.
S. No Groups Parameters
CRP (ng/ml) IL-6 (pg/ml) TNF-α (pg/ml)
1 Normal control 6369 ± 280 35.6 ± 1.17 162.4 ± 8.19
2 Normal control + α-mangostin (100 mg/kg) 6228 ± 471.6 35.2 ± 0.86 163 ± 9.33
3 Diabetic control 11837 ± 1437 57.8 ± 1.59 248.4 ± 16.72
4 α-Mangostin (25 mg/kg) 11452 ± 1059* 50.6 ± 2.99ns 236.2 ± 14.43*
5 α-Mangostin (50 mg/kg) 9424 ± 696.6*** 44.2 ± 1.28* 198.8 ± 13.85**
6 α-Mangostin (100 mg/kg) 6402 ± 305.2*** 36 ± 0.55*** 166.6 ± 9.54***
7 Glibenclamide (10 mg/kg) 6603 ± 186.3*** 37.4 ± 1.03*** 175 ± 10.6***
The data are expressed as mean ± SEM. (n = number of animals in each group = 6). The comparisons were made by one way ANOVA followed
by Dunnett’s test. ns = non-significant, TNF-α = Tumor necrosis factor α, CRP = C-reactive protein, IL-6 = Interleukin 6;.
* p < 0.05 is considered as very significant when compared to the control group.
** p < 0.01 is considered as very significant when compared to the control group.
*** p < 0.001 is considered as extremely significant when compared to the control group.
Fig. 11 – Oral glucose tolerance and AUC of α-mangostin in glucose-hyperglycemias animal model rats. Values are given as
mean ± S.E.M. of six rats in each group. *p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.001 compared with normal control values.
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droplet of fats and accumulation of fats. STZ induced dia-
betic rats treated with α-mangostin showed the improvement
of hepatocytes as well as central vein and reduced the
accumulation of fat droplets over the hepatocytes and improve
the liver cells (Fig. 12).
3.14.3. Renal
Renal histopathology studies of normal control and diabetic
control showed the significant difference in respect to tubular
dilation, focal necrosis (glomerulus), consolidation of the vas-
cular wall and tubular epithelial necrosis. A significant
difference was observed in diabetic control group and
α-mangostin group as for decreasing the glomerulus focal ne-
crosis; decrease the size of bowman capsules, consolidation
of the vascular wall, tubular epithelial necrosis (Figs. 13 and
14).
4. Discussion
Diabetes Mellitus (DM) is a deadly disease, consisting of chronic
disorder of carbohydrate, protein, fat, and lipidmetabolism char-
acterized by hyperglycemia resulting from the defects of insulin
action, insulin secretion, macrovascular (Stroke, heart attack
and vascular disease) and microvascular (Nephropathy,
retinopathy and neuropathy) complications (Badole and
Bodhankar, 2010; Irudayaraj et al., 2012).
An increased blood glucose level in glycemic rats and gly-
cemic rats treated with α-mangostin rats were observed in oral
glucose tolerance test (OGTT). The level of plasma insulin was
increased in the normoglycemic rats, while it was not changed
in glycemic rats in OGTT. Oral administration of α-mangostin
(25, 50 and 100mg/kg) and glibenclamide significantly (P < 0.001)
decreased the blood glucose level with changed plasma insulin
level. The possible mechanism action of α-mangostin on hy-
poglycemic effect may be involved its insulin like effects.
α-Mangostin increased the activity of pancreatic β-cells, re-
sulting in enhanced secretion of large amounts of insulin which
in turn brought down the blood glucose level (Nain et al., 2012).
From the result, it is assumed that α-mangostin could be re-
sponsible for the prompt for insulin and restoration of metabolic
activity.
STZ induced diabetic rats showed the effect on blood glucose
and insulin level due to abnormalities of β cell function
(Strandell et al., 1988). STZ induced diabetic rats treated with
different doses of α-mangostin declined the blood glucose level
and improved the plasma insulin level at dose dependent
manner (Table 3). Glibenclamide stimulated the plasma insulin
secretion from the pancreatic β cells and the blood glucose level
declined. STZ induced diabetic rats treated with different doses
of α-mangostin and glibenclamide had significantly (P < 0.001)
Fig. 12 – The effect of α-mangostin on pancreas histopathology in normal and STZ induced diabetic rats. (Original
magnification 40× , DXIT 1200, Nikon, Japan). (A) Normal control: Normal control group displays the average sized β cells
and normal islets (green arrow). (B) Diabetic Control: diabetic control rats pancreata histopathology showing the small sized
dilated and degranulated islet cells (yellow arrow) without amplification of the β cells (blue arrow). (C) Diabetic + α-
mangostin (25 mg/kg): treated rat pancreata showing the islets with endocrine cells, increasing more exocrine acini and
cytoplasm (white arrow) with enhancing of the sized of β cells (blue arrow). (D) Diabetic + α-mangostin (50 mg/kg): treated
rat pancreata showing the prominent hyper plasticity islet, granulated pancreatic islets (white arrow) and with enhancing
of the sized of β cells (blue arrow) (E) Diabetic + α-mangostin (100 mg/kg): treated rat pancreata showing the enlargement of
the β-cells with pink granules in the cytoplasm (brown arrow). (F) Diabetic + glibenclamide (10 mg/kg): treated rat pancreata
histopathology showing the hyper plasticity of islets and nonappearance, granulated islets with enlargement of (purple
arrow).
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declined plasma blood glucose level and improved pancre-
atic β cells. Based upon the result, probablemechanism of action
of α-mangostin may be to act on pancreatic β cells and start
the secretion of insulin.This hypothesis was confirmed by his-
topathology study of STZ induced diabetic rats treated with
α-mangostin which showed the protection of pancreatic β cells
from the toxic effect of STZ (Fig. 12).
STZ induced diabetic rats showed the increased level of blood
glucose and declined level of plasma insulin at the end of the
study. STZ induced diabetic rats treated with α-mangostin and
glibenclamide showed the enhanced level of plasma insulin.
Based upon the result, it can be hypothesized that α-mangostin
and glibenclamide showed the protective effect of pancreatic
β cells against the toxin (STZ) (Kumar et al., 2013a, 2013b, 2013c).
This hypothesis was confirmed by a pancreatic histopathol-
ogy study of STZ induced diabetic rats treated with α-mangostin
and glibenclamide. The histopathology study showed the
number of β cells did not increased but the size of present β
cells increased (Fig. 11).
Diabetes Mellitus is associated with weight loss. STZ induced
diabetic rats showed the body weight loss.The decreased level
of body weight was characterized by degradation of struc-
tural proteins and increased muscle destruction (Nain et al.,
2012). STZ induced diabetic rats treated with different doses
of α-mangostin and glibenclamide reversals of weight loss in-
dicated the restorative effect of α-mangostin. The possible
mechanism of action of α-mangostin may be due to reversal
of proteolysis, glycogenolysis and gluconeogenesis.
Type I and Type II diabetes often involve lipid metabolism
abnormality which is a metabolic disorder condition with dia-
betic complications viz., atherosclerosis, hypertriglyceridemia,
hypertension and hypercholestermia, which may contribute to
coronary artery diseases (Ferrannini et al., 1987; Krentz, 2003;
Zavaroni et al., 1987). Serum triglyceride and total choles-
terol level increased in hyperglycemia and produced the lipid
abnormality; lipid abnormality caused the glucose intoler-
ance (developing the diabetes) (Kumar et al., 2012). Under
normal conditions, insulin activates the lipoprotein lipase,which
hydrolyzes the triglycerides. The level of triglyceride in-
creased due to insulin deficiency, resulting it unable to activate
the lipoprotein lipase and causes the hypertriglyceridemia.
(Kumar et al., 2014). Under normal circumstances, HDL excre-
tion from the peripheral tissue.The increased level of LDL and
VLDL starts the cholesterol deposition in peripheral tissue and
decreased level of HDL not excreted from the peripheral tissue.
Hence, increased level of HDL and decreased level of VLDL
produce the atherogenic conditions (Ahmed et al., 2013). STZ
induced diabetic rats treated with α-mangostin significantly
(P < 0.001) brought back the lipid profile near to normal con-
dition.The possible mechanism of action of α-mangostin may
be to augment the level of insulin, which increases the utili-
zation of glucose, inhibits the hormonal sensitivity of lipase;
Fig. 13 – The effect of α-mangostin on liver histopathology study in STZ induced experimental rats after 56 days of
treatment. (Original magnification 40× , DXIT 1200, Nikon, Japan). (A) Normal control—Normal control group rats liver
showing the normal architecture and hepatic cells. (B) Diabetic control: diabetic control rats histopathology clearly showing
the hepatocellular necrosis and extensive vocalization with the vanishing of nuclei with disordered of the liver structure
(green arrow). (C) Diabetic + α-mangostin (25 mg/kg): treated rats showing the fibrotic changes, hepatocellular necrosis and
fat deposition (green arrow) (D) Diabetic + α-mangostin (50 mg/kg): treated rats showing the fat deposition, fibrotic changes
and the hepatocellular necrosis (green arrow) (E) Diabetic + α-mangostin (100 mg/kg): treated rats showing the normal
nucleus, cytoplasm and hepatocellular architecture. (F) Diabetic + glibenclamide (10 mg/kg): treated rats showing the
distinct hepatic layer, cytoplasm and normal heptocellular architecture.
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and declines the deposition of fatty acids.The atherogenic index
and coronary risk factor also efficient protector of lipid low-
ering therapy. This hypothesis was confirmed by the liver
histopathology studies of α-mangostin treated groups (Fig. 5).
Liver is an important organ, which plays an important role
in the synthesis of glycogen and protection of postprandial hy-
perglycemia (Kumar et al., 2013a, 2013b, 2013c). Constant
hyperglycemia is leads to development of many complications
during diabetes, such as neuropathy andmicrovascular (Laakso
et al., 1995). In normal circumstances, liver plays an important
role in the ruling of glucose metabolizing enzymes viz., hexo-
kinase, glucose-6-phosphatase and fructose-1-6-biphosphate.
Several studies confirmed that the reduced level of fructose-1-
6-biphosphate, glucose-6-phosphatase and enhanced level of
hexokinase observed during the diabetes condition, same was
observed in the current study. Hexokinase is one of the most
important enzyme which plays an important role in conver-
sion of glucose into glucose-6-phosphatase (Baquer et al., 1998;
Latha and Pari, 2003). Declined level of hexokinase, decreases
the conversion of glucose into glucose-6-phosphatase and uti-
lization of energy.Glucose-6-phosphatase regulates the glucose
metabolizing enzymes. STZ induced diabetic rats showed the
increased level of glucose-6-phosphatase which declined the
glucose metabolizing enzymes and enhanced the fat deposi-
tion in liver (Liu et al., 1994). The deposition of fats in liver has
been supported by histopathology studies of STZ induced dia-
betic rats. Fructose-1-6-biphosphate is another enzyme which
takes part in the conversion of glucose into energy and glycoly-
sis (Kumar et al., 2014). The possible mechanism action of
α-mangostin may be increasing the insulin level, which im-
proves the glycolysis and declines the gluconeogenesis.
The increase level of free radicals causes the hyperglyce-
mia, followed by production of oxidative stress, which can
increase the level of lipid oxidation, alter endogenous anti-
oxidant defense and further impairment of glucose metabolism
in biological system (Bansala et al., 2012). Oxidative stress, ini-
tiating to decrease the endogenous antioxidant status and
improper control of deleterious effects of free radicals, plays
an important role in the macrovascular andmicrovascular con-
dition during diabetes (Ceriello et al., 2000). During the oxidative
stress, reduction of superoxide radical (O2) and hydrogen per-
oxide radical (H2O2) are playing an important role in cellular,
tissue damaging and causing a variety of diabetes condi-
tions. DM conditions and endogenous antioxidant levels were
decreased and start damaging organ due to generation of oxi-
dative stress by free radicals (Memis¸og˘ullari and Bakan, 2004).
SOD and CAT, is the first line endogenous scavenging enzymes
that remove or decrease the level of free radicals. SOD and CAT
content decreased in liver, kidney and pancreas during the dia-
betes mellitus.The declining level of free radicals in vital organs,
Fig. 14 – The effect of α-mangostin on kidney histopathology in normal and STZ induced diabetic rats. (Original
magnification 40× , DXIT 1200, Nikon, Japan). (A) Normal control: normal control rat kidney histopathology showing the
average size of glomerulus with an average size of tubulus, baseline and average sizes of bowman capsule (yellow arrow).
(B) Diabetic Control: diabetic control rats showing the destroyed glomerulus with deposition of fats on baseline and served
the glomerulosclerosis, bigger size of bowman capsule (red arrow) and inflamed blood vessels, lymphocytes (white arrow).
(C) Diabetic + α-mangostin (25 mg/kg): treated rat kidney showing the inflamed blood vessels (white arrow) and fat
deposition (red arrow). (D) Diabetic + α-mangostin (50 mg/kg): treated rat kidney showing the fat deposition with less
inflamed blood cells (red arrow). (E) Diabetic + α-mangostin (100 mg/kg): treated rat kidney showing the average size of
glamorous without inflammation in blood vessels and enhance the tubule structure. (F) Diabetic + glibenclamide (10 mg/
kg): treated rat kidney histopathology showing the average size of glomerulus without inflammatory blood vessels.
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starts the accumulation of superoxide, hydrogen peroxide anion
and starts the generation of delicious radicals such as hy-
droxyl (OH), resulting in the spreading of lipid peroxidation
(LPO). LPO is one of the common characteristic features of dia-
betes mellitus. Continuous production of free radicals such as
superoxide and hydrogen peroxide starts peroxidation of un-
saturated free fatty acids and damaging the tissue and attacking
the membranes (Balasubashini et al., 2004; Ravi et al., 2004).
Continuous generation of free radicals can lead to increased
level of LPO, increased levels of LPO damage the membrane
and cause dysfunction (Alfy et al., 2005). On the other hand,
increased production of superoxide decreased the level of LPO.
STZ induced diabetic rats treated with α-mangostin and showed
enhanced levels of LPO as compared to diabetic rats. Levels of
SOD and CAT in the organ decreased due to activation of
glycation by enzymes (Yan and Harding, 1997). SOD plays an
important role in the conversion of the delicious anions like
superoxide into hydrogen peroxide, which showed the effect
on the damaging membrane and biological structures. Another
first line antioxidant such as CAT, convert the hydrogen per-
oxide into hydroxyl radicals and protect the tissue from highly
reactive hydroxyl radicals. STZ induced diabetic rats treated
with different doses of α-mangostin significantly (P < 0.001) in-
creased the level of hepatic and renal SOD, CAT and claimed
the antioxidant effect of α-mangostin.Transitional metal reacts
with peroxide and generate the delicious hydroxyl radical
(Halliwell and Gutteridge, 1999). The increased level of SOD;
increased the level of GPx and showed the overload of perox-
ide in the cells. The possible mechanism of action of
α-mangostin may be due to declined levels of reactive free radi-
cals, which either reduced the glycation of enzymes or
enhanced the level of endogenous antioxidant levels.The result
clearly showed that α-mangostin contains the free radical scav-
enging activity, which could be a beneficial action against the
hydrogen peroxide, hydroxyl and superoxide radicals, which
caused the pathological alteration.
The storage of glucose in the form of intracellular stor-
able, glycogen plays an important role in the storage of glucose.
Diabetes mellitus shows the effect on liver of impairment of
the normal capacity to synthesize glycogen (Pandit et al., 2010).
In normal conditions, insulin activates the intracellular gly-
cogen storage by inhibiting the glycogen phosphorylase and
enhancing the synthesis of glycogen (Chandramohan et al.,
2008). Declined levels of hepatic glycogen were observed in STZ
induced diabetic rats. STZ induced diabetic rats treated with
α-mangostin showed the significantly (P < 0.001) enhanced the
level of hepatic glycogen indicating the improved of the gly-
cogen storage in diabetic condition.
In normal circumstances, small volume of blood glucose and
3.4–5.8% of hemoglobin has been covalently bonded to red blood
cells in hemoglobin. During diabetes production of free radi-
cals and blood glucose level in blood are increased. Glycation
is directly propositional to hyperglycemia. Some of researcher
claim that the increased rate of blood glucose, which in-
creased the glycation and glycation itself increased the
generation of free radicals during the diabetes conditions.
Glycated hemoglobin used as amarker of oxidative stress during
the diabetic conditions (Bravi et al., 2006). During the diabetic
condition, level of glycated hemoglobin is increased due to en-
hanced blood glucose. Enhanced level of blood glucose starts
by adding the hemoglobin in N terminus and improving the
level of glycated hemoglobin (Klujber et al., 1979). STZ induced
diabetic rats showed the increased level of glycated hemoglo-
bin at end of the experiment. STZ induced diabetic rats treated
with α-mangostin showed the level of glycated hemoglobin has
decreased. The possible mechanism of action of α-mangostin
may be due to decline in the blood glucose level and enhance-
ment in the endogenous antioxidant level.
Liver is a vital organ of body for detoxification, metabo-
lism, storage of xenobiotics and their metabolites. SOGT, SGPT
and ALP are the biological markers of liver function. During
the diabetes condition, SGOT, SGPT and ALP levels are in-
creased due to the release of these enzymes into the liver
cytosol from the blood stream (Mahendrn et al., 2014). These
hepatic marker released into the blood stream showed the
hepatic toxic effects (Ramesh et al., 2010). STZ induced dia-
betic rats showed the increased level of hepatic marker and
showed the hepatic toxicity. STZ induced diabetic rats treated
with α-mangostin showed the systematic declined level of
hepatic markers and confirmed the hepato-protective effect
of α-mangostin. The possible mechanism of action of
α-mangostin may be due to decline in the blood glucose level
and hepatic biomarker. This hypothesis was confirmed from
the liver histopathology studies. The diabetic liver histopa-
thology showed the necrosis and inflamed blood vessels, which
are improved in α-mangostin treated group rats at effective dose
dependent manner.
STZ induced diabetic rats showed the enhanced level of cre-
atinine, BUN and declined level of total protein as comparison
to normal control group rats. Enhanced level of creatinine, BUN
and declined level of total protein showed the renal dysfunc-
tion. Some researchers claim that the increased level of
creatinine and BUN are waste products of metabolism and
causes the renal injury or toxicity. Enhanced level of creati-
nine and BUN due to degradation of protein and decreasing
the glamor filtration rate (Ahmed et al., 2014, 2015). In our study,
STZ induced diabetic rats treated with α-mangostin showed
the declined level of creatinine, BUN and enhanced level of total
protein.The possible mechanism of action of α-mangostin may
be declined by the degradation of protein.We observed the less
focal necrosis and tubular epithelial necrosis in the renal his-
topathology of treated group, which provide the support to our
hypothesis. (Fig. 12).
Inflammation plays an important role in the expansion of
type II diabetes and reduced the insulin sensitivity. Inflam-
matory markers such as CRP andTNF-α are circulating markers
of low grade inflammation and vascular injury. The elevated
level of CRP is linked with glucose tolerance, obesity, and insulin
resistance; increased level of CRP also involved in the increas-
ing the blood glucose level and the etiology of type II diabetes
(Hu et al., 2004). Generally, CRP produced and secreted from
the liver under the encouragement of cytokines such as IL-6
and TNF-α. IL-6 showed the effect on insulin induced glucose
by altering insulin receptor, glut-4 and IRS, which starts the
expansion and progression of insulin resistance (Khan et al.,
2013). In our experimental study, levels of CRP,TNF-α and IL-6
significantly increased and showed the symptoms of type II
diabetes. STZ induced diabetic rats treated with α-mangostin
showed themarked alteration in the level of the serum cytokine.
The level of the IL-6 and CRP declined by the treatment with
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α-mangostin showed the reduction in the insulin resistance.
The possible mechanism of action of α-mangostin may be due
to increased level of the cytokine mediators and provide the
anti-inflammatory effect (Ramprasath et al., 2006).
5. Conclusion
A significant improvement in the insulin, hemoglobin, hexo-
kinase, endogenous antioxidant enzymes, renal parameters,
hepatic enzymes, lipid profile and declining level of glycated
hemoglobin, fructose-1-6-biphosphatase, glucose-6-Phosphatase
were observed among STZ induced diabetic rats treated with
α-mangostin. It is thus concluded that α-mangostin is a prom-
ising antidiabetic, antihyperlipidemic, hepatoprotective, renal
protective, free radical scavenger compound. α-Mangostin also
improved the various abnormalities of diabetic conditions in
the STZ induced diabetic rats. The mode of action of
α-mangostin may depend on the many factors viz., animal (age,
sex, health, time of treatment), drug (concentration), route of
administration (oral gavage, injection, supplement), and dia-
betic model used. As we have already discussed, at different
doses, α-mangostin can either act to improve the insulin level
or act as a free radical scavenger by increasing the activity of
endogenous antioxidant enzymes, and possibly act through a
novel mechanism of action yet to be discovered.
It can be concluded that α-mangostin could be used in the
clinical management of diabetes. The therapeutic effects of
α-mangostin can be endorsed to their action on insulin resis-
tance, oxidant–antioxidant system, hyperlipidemia, renal,
hepatic and inflammation process.
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